• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

FOXO3a protects glioma cells against temozolomide-induced DNA double strand breaks via promotion of BNIP3-mediated mitophagy
In this study we investigated the role of FOXO3a in regulating the sensitivity of glioma cells to temozolomide (TMZ) and its relationship with BNIP3-mediated mitophagy. We showed that TMZ dosage-dependently inhibited the viability of human U87, U251, T98G, LN18 and rat C6 glioma cells with IC50 values of 135.75, 128.26, 142.65, 155.73 and 111.60 μM, respectively. In U87 and U251 cells, TMZ (200 μM) induced DNA double strand breaks (DSBs) and nuclear translocation of apoptosis inducing factor (AIF), which was accompanied by BNIP3-mediated mitophagy and FOXO3a accumulation in nucleus. TMZ treatment induced intracellular RO...
Source: Acta Pharmacologica Sinica - April 21, 2021 Category: Drugs & Pharmacology Authors: Chuan He Shan Lu Xuan-Zhong Wang Chong-Cheng Wang Lei Wang Shi-Peng Liang Tian-Fei Luo Zhen-Chuan Wang Mei-Hua Piao Guang-Fan Chi Peng-Fei Ge Source Type: research

Micro-RNA29b Enhances the Sensitivity of GlioblastomaMultiforme Cells to Temozolomide by Promoting Autophagy.
CONCLUSION: miR-29b potentiates TMZ sensitivity against GBM cells by inducing autophagy and the combined use of miR-29 mimic and TMZ might represent a potential therapeutic strategy for GBM patients. This article is protected by copyright. All rights reserved. PMID: 32275350 [PubMed - as supplied by publisher]
Source: Anatomical Record - April 9, 2020 Category: Anatomy Authors: Xu JX, Yang Y, Zhang X, Luan XP Tags: Anat Rec (Hoboken) Source Type: research

Cancers, Vol. 10, Pages 492: Recent Advances in Oncolytic Virotherapy and Immunotherapy for Glioblastoma: A Glimmer of Hope in the Search for an Effective Therapy?
nin To date, no targeted drugs, antibodies or combinations of chemotherapeutics have been demonstrated to be more efficient than temozolomide, or to increase efficacy of standard therapy (surgery, radiotherapy, temozolomide, steroid dexamethasone). According to recent phase III trials, standard therapy may ensure a median overall survival of up to 18–20 months for adult patients with newly diagnosed glioblastoma. These data explain a failure of positive non-controlled phase II trials to predict positive phase III trials and should result in revision of the landmark Stupp trial as a historical control for ...
Source: Cancers - December 5, 2018 Category: Cancer & Oncology Authors: Aleksei A. Stepanenko Vladimir P. Chekhonin Tags: Review Source Type: research

YB-1 dependent oncolytic adenovirus efficiently inhibits tumor growth of glioma cancer stem like cells
Conclusion: The results of this study supported YB-1 based virotherapy as an attractive therapeutic strategy for GBM treatment which will be exploited further in multimodal treatment concepts.
Source: Journal of Translational Medicine - September 18, 2013 Category: Research Authors: Klaus MantwillUlrike NaumannJanina SeznecVroni GirbingerHermann LagePawel SurowiakDagmar BeierMichel MittelbronnJürgen SchlegelPer Holm Source Type: research